Autologous T cells are genetically engineered ex vivo to express a chimeric antigen receptor that recognizes B‑cell antigens. After infusion, these CAR‑T cells bind and kill B cells and plasma‑lineage cells, depleting pathogenic B cells, reducing autoantibody production, and disrupting B–T cell interactions/antigen presentation to dampen downstream inflammatory responses and enable immune reconstitution.